Figure 3. SR9009 Induces Wakefulness and Suppresses Sleep.

A, Mice injected with the REV-ERB agonist SR9009 (i.p. 100 mg kg⁻¹) at ZT6 display an increase in wakefulness as detected by EEG. B, SR9009 increases SWS and REM sleep latency C, Locomotor telemetry data indicating an increase in movement during the period 2h after ZT6 injection of SR9011. Mice in A, B, and C were maintained under 12h:12h L:D conditions. D, Mice injected with SR9009 (i.p. 100 mg kg⁻¹) at CT6 under constant dark conditions show increased wakefulness. E, SR9009 increases SWS and REM sleep latency when injected at CT6 under constant dark conditions. Data are expressed mean ± SEM. All EEG graphs are plotted per 1 h for a 24 h period. Values are mean ± SEM (n=8 for EEG studies and n=6 for telemetry studies). (C)). Within the EEG studies (wakefulness, SWS and REM sleep), potential differences between treatments were assessed by repeated measure two-way ANOVA followed by Bonferroni post hoc test. In panels examining latency and activity, differences between treatment groups (vehicle vs. SR) were assessed by a two tailed t test (Student’s) with significance *P < 0.05. Experiments were performed at least twice.